Start here if you're new
what it is
TriMas makes engineered parts for packaging, airplanes, and industrial customers.
how it gets paid
Last year Trimas made $646M in revenue. Packaging was the main engine at $0.36B, or 55% of sales.
why it's growing
Revenue grew 2.4% last year. Revenue in the latest quarter was $786M. Yahoo Finance shows $646M in trailing revenue.
what just happened
TriMas $0.40 EPS beat the $0.21 estimate, but the margin line stayed ugly at 4.2%.
At a glance
B+ balance sheet — decent shape, but not bulletproof
75/100 earnings predictability — reasonably predictable
31.1x trailing p/e — you're paying up for this one
0.4% dividend yield — cash in your pocket every quarter
7.5% return on capital — nothing to write home about
xvary composite: 64/100 — average
What they do
TriMas makes engineered parts for packaging, airplanes, and industrial customers.
Its edge is boring scale. Packaging is 55% of sales, and aerospace is 32%. That split means your business does not lean on one customer or one plant. If you are the buyer, switching suppliers is painful, because custom parts take time and money to requalify.
How they make money
$646M
annual revenue · their business grew +2.4% last year
Packaging
$0.36B
+4.0%
Aerospace
$0.21B
N/A
Specialty Products
$0.08B
N/A
The products that matter
engineered packaging components
Packaging
sales up 4% in the first nine months of 2025
this looks like the steadiest part of the portfolio right now. sales rose 4% in the first nine months of 2025, which matters because not much else in the story has been clean.
relative stability
industrial and specialty components
Specialty products
sales down 9% in the first nine months of 2025
this has been the laggard. sales fell 9%, and management commentary points to weaker operating performance too. if you want the turnaround to stick, this segment has to stop subtracting.
current weak spot
aerospace business being sold
Aerospace division
$1.45B sale value
this matters because the agreed sale price is enormous relative to a ~$2B market cap. if the deal closes by the end of q1 2026, the capital-allocation question gets louder than the operating one.
deal changes the story
Key numbers
17%
upside
's $42 target sits 17% above the $35.81 price. That is a real gap, not a moonshot.
6.4%
op margin
Every $100 of sales leaves $6.40 after operating costs. That is thin when the revenue base is only $646M.
7.5%
return on capital
The business earns $7.50 for every $100 invested. That is better than cash, but not by much.
21%
debt/capital
Debt is 21% of capital, so the balance sheet is fine until rates or margins wobble.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 55 / 100
- long-term debt $407M (21% of capital)
- net profit margin 7.5% — keeps 8 cents of every dollar in revenue
- return on equity 12% — $0.12 profit for every $1 investors have put in
B+ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in TRS 3 years ago → it's now worth $13,400.
The index would have given you $13,920.
source: institutional data · total return
What just happened
beat estimates
TriMas $0.40 EPS beat the $0.21 estimate, but the margin line stayed ugly at 4.2%.
Revenue in the latest quarter was $786M. Yahoo Finance shows $646M in trailing revenue, so the time windows do not match cleanly. The only clean read is that EPS beat the bar while gross margin stayed thin.
$786M
revenue
$0.40
eps
4.2%
gross margin
EPS beat
The $0.40 EPS print mattered because it beat the $0.21 estimate by 90.48%.
-
trimas has agreed to sell its aerospace division.under the terms of the deal, investment firm tinicum l.p. will pay $1.45 billion for the segment, with the transaction expected to close by the end of the first quarter of 2026. (blackstone will be a minority investor in the business.) leadership had been exploring strategic alternatives for the company, and believes the sale will allow trimas to be more focused on its packaging platform.
-
meanwhile, 2025 was likely a good bounce-back year for the maker of engineered products. (it was set to release full-year financials in early february.) during the first three quarters, sales increased 13% from the like-2024 period, and probably expanded about 11% for 2025 as a whole.earnings per share recovered sharply in the first nine months of 2025, and may have nearly doubled in the year just ended, to $1.15.
-
that said, operating results across its three reporting segments have been uneven. (as per our convention, aerospace will be treated as continuing operations until the sale has closed.) sales in the aerospace unit jumped 37% during the first nine months of 2025, and operating profits more than doubled, thanks to strong demand for precision fasteners and tubular products.
-
in the packaging business, sales climbed 4% during the first three quarters, but operating profit was flattish due to a mix shift to lower-margined products.
-
specialty products has been a laggard, with sales down 9% and operating profit falling by more than half.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is turning a $1.45B aerospace sale into actual per-share value.
med
the aerospace sale slips or closes on worse terms
The company expects the $1.45B transaction to close by the end of q1 2026. If timing slips or economics change, the main reason investors are paying attention gets weaker fast.
Impact: this is a deal equal to roughly 73% of the current market cap, so execution matters more than usual.
med
specialty products keeps dragging on results
Sales in Specialty products fell 9% in the first nine months of 2025. If that segment stays weak, the post-sale company may look smaller without looking better.
Impact: with only a 5.1% net margin on the annual base, there is not much room for another weak segment to hide.
med
tariffs and supply chain friction hit a thin-margin model
TRS makes physical products. That means input costs, freight, and tariff exposure still matter. In a business with a 5.1% net margin, even modest cost pressure can do visible damage.
Impact: you don't need a crisis here. A small margin squeeze on $646M of revenue is enough to change the earnings story.
med
the sale closes, but the cash gets misused
Selling a major asset is one decision. What management does next is the second one, and it is usually the part that decides shareholder returns.
Impact: if returns on capital stay around 5.0%, the market may stop giving management credit for portfolio moves and start asking harder questions.
If margins drift back toward 5.1% and the sale does not translate into better per-share economics, you are left with a 31.1x trailing multiple on a business that still looks operationally uneven.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
aerospace sale closing window
management expects the $1.45B aerospace sale to close by the end of q1 2026. if that slips, the whole setup gets less clean.
trend
specialty products stabilization
sales were down 9% in the first nine months of 2025. you want that decline to flatten before calling this a real operating reset.
metric
net margin after the headline quarter
q3 printed a 30.3% net margin, but the annual base is 5.1%. watch where the normalized number settles.
risk
what management does with the proceeds
the next chapter is not just about selling aerospace. it's about whether the cash raises returns above the current 5.0% on capital.
Analyst rankings
short-term outlook
top 20%
momentum score 2 — in human-speak, analysts think the stock has better near-term odds than most.
risk profile
average
stability score 3 — this is middle-of-the-pack risk, not a bunker stock and not a chaos stock.
chart momentum
average
technical score 3 — the chart is behaving normally. no major technical message beyond that.
earnings predictability
75 / 100
results have been reasonably predictable. the problem is less surprise and more whether the normalized earnings base is strong enough.
source: institutional data
Institutional activity
institutions have been net buying for 2 consecutive quarters — 112 buyers vs. 83 sellers in 3q2025. total institutional holdings: 39.0M shares. net buying for 2 quarters.
source: institutional data
Price targets
3-5 year target range
$25
$58
$36
current price
$42
target midpoint · +17% from current · 3-5yr high: $50 (+40% · 9% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive